2X1:ETR
Abivax SA
၇၇.၁၀ €
arrow_upward
+၀.၂၆%(+၀.၂၀) 1D
အောက် ၁၄, GMT+၂ ၀၉:၀၄:၄၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
၇၇.၁၀ €
High
၇၇.၁၀ €
Low
၇၇.၁၀ €
Mkt. cap
၆၇၉.၆၇ ဋေ
Avg. vol.
၁.၇၉ ထောင်
Volume
၅.၀၀
52-wk high
၁၃၇.၄၀ €
52-wk low
၆၀.၈၅ €
EPS
-၅.၂၀ €
No. of employees
၉၈
Open
၇၇.၁၀ €
High
၇၇.၁၀ €
Low
၇၇.၁၀ €
Mkt. cap
၆၇၉.၆၇ ဋေ
Avg. vol.
၁.၇၉ ထောင်
Volume
၅.၀၀
52-wk high
၁၃၇.၄၀ €
52-wk low
၆၀.၈၅ €
EPS
-၅.၂၀ €
No. of employees
၉၈
News stories
From web sources and news partners
Idéal Investisseur
·
ပြီးခဲ့သည့် ၁၉ နာရီ
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com